Ocular Science Expands Advisory Board with Appointment of Houston Surgeon David Szynkarski, MD, MBA
Ocular Science®, a biotech company dedicated to advancing patient-centered ophthalmic solutions, is proud to announce the addition of David Szynkarski, MD, MBA, to its distinguished Medical Advisory Board.
A Texas native, Dr. Szynkarski earned his B.S. in Biomedical Engineering, M.D., and M.B.A. at Texas A&M University, where he was inducted into the Alpha Omega Alpha Honor Medical Society. He completed residency at the University of Texas Medical Branch and attended fellowship training in refractive and cataract surgery at Parkhurst NuVision in San Antonio.
Widely respected for his surgical expertise and scholarly contributions, Dr. Szynkarski earned recognition as Resident Research Champion for his innovative work during training. Beyond his clinical practice, he has led medical mission trips to Peru, Nepal, and the Dominican Republic, providing sight-restoring surgery and training to underserved populations.
In his surgical routine, Szynkarski relies on OSRX, Ocular Science’s 503B pharmacy affiliate specializing in ophthalmic medications for post-operative care, combination therapy, and low-dose atropine. “What drew me to Ocular Science is simple: a patient-first philosophy paired with a bold approach to innovation. As part of the Medical Advisory Board, I’m eager to help turn new ideas into therapies that truly change the way we care for patients.“
Company leadership echoed that sentiment. “Dr. Szynkarski represents the next generation of ophthalmic leadership,” said Eric Garner, Ocular Science Chief Commercial Officer. “He combines surgical skill and research rigor with the kind of fresh ideas that drive innovation. Just as important, his humanitarian work underscores the patient-first focus we want guiding our Medical Advisory Board.”
The Ocular Science Medical Advisory Board brings together 32 leading ophthalmologists and optometrists to guide product strategy and ensure innovations are clinically relevant and impactful. Dr. Szynkarski’s appointment strengthens this effort and reinforces the company’s commitment to shaping the future of eye care.
ABOUT OCULAR SCIENCE
Ocular Science®, headquartered in El Segundo, Calif., is a leading biotech company founded in 2015 by CEO Anthony Sampietro, Chief Medical Officer Damien Goldberg, MD, and Francis Mah, MD. The company focuses on the production, marketing, and sales of compounded ophthalmic products and is guided by a medical advisory board of world leaders in ophthalmology.